Rocket One Inc. Common Stock (NASDAQ:RKTO) Posts Quarterly Earnings Results

Rocket One Inc. Common Stock (NASDAQ:RKTO) released its earnings results on Friday. The company reported ($0.11) earnings per share for the quarter, FiscalAI reports.

Rocket One Inc. Common Stock Stock Down 7.0%

NASDAQ RKTO traded down $0.02 on Friday, reaching $0.32. The company had a trading volume of 219,607 shares, compared to its average volume of 3,835,937. The stock’s 50 day moving average is $0.61 and its 200-day moving average is $0.82. The stock has a market cap of $7.99 million, a price-to-earnings ratio of -0.39 and a beta of 1.01. Rocket One Inc. Common Stock has a 52 week low of $0.32 and a 52 week high of $2.45.

Hedge Funds Weigh In On Rocket One Inc. Common Stock

An institutional investor recently raised its stake in Rocket One Inc. Common Stock stock. Lido Advisors LLC raised its stake in shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) by 100.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,000 shares of the company’s stock after buying an additional 19,500 shares during the quarter. Lido Advisors LLC owned about 0.20% of Rocket One Inc. Common Stock worth $33,000 at the end of the most recent reporting period. 7.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RKTO. Weiss Ratings upgraded shares of Rocket One Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 29th. Wall Street Zen upgraded shares of Rocket One Inc. Common Stock from a “strong sell” rating to a “sell” rating in a report on Sunday, October 25th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Rocket One Inc. Common Stock currently has an average rating of “Hold” and a consensus price target of $5.00.

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.